SCHEMBL15375360

SCHEMBL15375360

CCc1ccccc1OCc1cc(Cl)ccc1C(O)C#N

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 1/20 0.47
MRGPRX4 Q96LA9 3/20 0.40
MAPT P10636 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
PKM P14618 1/20 0.39
PTGER1 P34995 5/20 0.39
FNTA P49354 1/20 0.38
FNTB P49356 1/20 0.38
CYP1A2 P05177 1/20 0.37
CYP2D6 P10635 1/20 0.37
FABP4 P15090 1/20 0.37
FABP5 Q01469 1/20 0.37
KDM4E B2RXH2 1/20 0.37
LMNA P02545 1/20 0.37
MAPK1 P28482 1/20 0.37
SGMS2 Q8NHU3 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15375471 0.87 PTGDR2 (0.48) PTGDR2MAPTL3MBTL1MEN1KMT2A
SCHEMBL28038065 0.87 PTGDR2 (0.48) PTGDR2MAPTL3MBTL1MEN1KMT2A
SCHEMBL15375461 0.86 MAPT (0.46) PTGDR2MAPTNPSR1L3MBTL1MEN1
SCHEMBL27940412 0.86 POLB (0.39) PTGDR2MRGPRX4MAPTL3MBTL1MEN1
SCHEMBL15375617 0.86 POLB (0.39) PTGDR2MRGPRX4MAPTL3MBTL1MEN1
SCHEMBL15375550 0.86 SGMS2 (0.41) PTGDR2MRGPRX4L3MBTL1MEN1KMT2A
SCHEMBL15375643 0.82 FABP4 (0.54) PTGDR2MRGPRX4PTGER1FABP4FABP5
SCHEMBL15402016 0.81 PTGDR2 (0.50) PTGDR2MRGPRX4MAPTNPSR1L3MBTL1
SCHEMBL15401682 0.80 PTGDR2 (0.46) PTGDR2MRGPRX4MEN1KMT2APKM
SCHEMBL15375383 0.80 PTGDR2 (0.43) PTGDR2MRGPRX4NPSR1CYP1A2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2682382-B1 Method for Producing Phenylacetamide Compound SUMITOMO CHEMICAL CO (JP) 2016-11-23 EP disclosed
EP-2662352-B1 Method for Producing Phenylacetamide Compound SUMITOMO CHEMICAL CO (JP) 2016-11-09 EP disclosed
EP-2397459-B1 METHOD FOR PRODUCING PHENYLACETAMIDE COMPOUND SUMITOMO CHEMICAL CO (JP) 2015-12-16 EP disclosed
EP-2682382-A2 Method for Producing Phenylacetamide Compound Sumitomo Chemical Company, Limited (JP) 2014-01-08 EP disclosed
US-8624062-B2 Method for producing phenylacetamide compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2014-01-07 US disclosed
EP-2662352-A2 Method for Producing Phenylacetamide Compound Sumitomo Chemical Company, Limited (JP) 2013-11-13 EP disclosed
EP-2397459-A1 METHOD FOR PRODUCING PHENYLACETAMIDE COMPOUND Sumitomo Chemical Company, Limited (JP) 2011-12-21 EP disclosed
US-20110295035-A1 METHOD FOR PRODUCING PHENYLACETAMIDE COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-12-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110295035-A1 METHOD FOR PRODUCING PHENYLACETAMIDE COMPOUND MRPL21, AADAC, ARSA PTGDR2 938/4885MRGPRX4 1236/4885MAPT 3967/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.